Washington University School of Medicine

Digital Commons@Becker
Open Access Publications
2015

An international multicenter retrospective study of Pseudomonas
aeruginosa nosocomial pneumonia: Impact of multidrug
resistance
Scott T. Micek
St. Louis College of Pharmacy

Richard G. Wunderink
Northwestern University

Marin H. Kollef
Washington University School of Medicine in St. Louis

Catherine Chen
Washington University School of Medicine in St. Louis

Jordi Rello
Vall d’Hebron University Hospital

See next page for additional authors
Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Recommended Citation
Micek, Scott T.; Wunderink, Richard G.; Kollef, Marin H.; Chen, Catherine; Rello, Jordi; Chastre, Jean;
Antonelli, Massimo; Welte, Tobias; Clair, Bernard; Ostermann, Helmut; Calbo, Esther; Torres, Antoni;
Menichetti, Francesco; Schramm, Garrett E.; and Menon, Vandana, ,"An international multicenter
retrospective study of Pseudomonas aeruginosa nosocomial pneumonia: Impact of multidrug resistance."
Critical Care. 19,. 219. (2015).
https://digitalcommons.wustl.edu/open_access_pubs/4565

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been
accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker.
For more information, please contact vanam@wustl.edu.

Authors
Scott T. Micek, Richard G. Wunderink, Marin H. Kollef, Catherine Chen, Jordi Rello, Jean Chastre, Massimo
Antonelli, Tobias Welte, Bernard Clair, Helmut Ostermann, Esther Calbo, Antoni Torres, Francesco
Menichetti, Garrett E. Schramm, and Vandana Menon

This open access publication is available at Digital Commons@Becker: https://digitalcommons.wustl.edu/
open_access_pubs/4565

Micek et al. Critical Care (2015) 19:219
DOI 10.1186/s13054-015-0926-5

RESEARCH

Open Access

An international multicenter retrospective study
of Pseudomonas aeruginosa nosocomial
pneumonia: impact of multidrug resistance
Scott T Micek1*, Richard G Wunderink2, Marin H Kollef3, Catherine Chen3, Jordi Rello4, Jean Chastre5,
Massimo Antonelli6, Tobias Welte7, Bernard Clair8, Helmut Ostermann9, Esther Calbo10, Antoni Torres11,
Francesco Menichetti12, Garrett E Schramm13 and Vandana Menon14

Abstract
Introduction: Pseudomonas aeruginosa nosocomial pneumonia (Pa-NP) is associated with considerable morbidity,
prolonged hospitalization, increased costs, and mortality.
Methods: We conducted a retrospective cohort study of adult patients with Pa-NP to determine 1) risk factors for
multidrug-resistant (MDR) strains and 2) whether MDR increases the risk for hospital death. Twelve hospitals in 5
countries (United States, n = 3; France, n = 2; Germany, n = 2; Italy, n = 2; and Spain, n = 3) participated. We
compared characteristics of patients who had MDR strains to those who did not and derived regression models to
identify predictors of MDR and hospital mortality.
Results: Of 740 patients with Pa-NP, 226 patients (30.5%) were infected with MDR strains. In multivariable analyses,
independent predictors of multidrug-resistance included decreasing age (adjusted odds ratio [AOR] 0.91, 95%
confidence interval [CI] 0.96-0.98), diabetes mellitus (AOR 1.90, 95% CI 1.21-3.00) and ICU admission (AOR 1.73, 95%
CI 1.06-2.81). Multidrug-resistance, heart failure, increasing age, mechanical ventilation, and bacteremia were
independently associated with in-hospital mortality in the Cox Proportional Hazards Model analysis.
Conclusions: Among patients with Pa-NP the presence of infection with a MDR strain is associated with increased
in-hospital mortality. Identification of patients at risk of MDR Pa-NP could facilitate appropriate empiric antibiotic
decisions that in turn could lead to improved hospital survival.

Introduction
Recent trends show an increase in the prevalence of nosocomial pneumonia (NP) caused by multidrug-resistant
(MDR) Gram-negative bacteria, most commonly Pseudomonas aeruginosa with documented resistance to β-lactams,
carbapenems, aminoglycosides, and fluoroquinolones [1-3].
Consequently, the therapeutic effectiveness of current
therapies for bacterial NP is becoming increasingly limited, emphasizing the need for development of new and
effective antimicrobials as well as novel strategies to prevent resistance emergence [4,5].
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Nosocomial pneumonia due to P. aeruginosa (Pa-NP)
is associated with considerable morbidity, prolonged
hospitalization, increased costs, and mortality [6-8]. P.
aeruginosa is one of the few pathogens independently
associated with increased mortality among patients with
sepsis or pneumonia in the ICU setting [6,9]. The mortality associated with Pa-NP is further increased when
inappropriate initial antibiotic therapy (IIAT) is prescribed, usually due to the presence of MDR pathogens
[10-13]. The overall impact of Pa-NP on clinical outcomes and healthcare costs underscores the importance
of this nosocomial infection. Therefore, we performed a
multinational study with the following objectives: first,
to evaluate the prevalence of MDR Pa-NP and to identify clinical risk factors associated with MDR Pa-NP;
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second, to evaluate the influence of MDR status on patient outcomes.

Methods
Study design and ethical standards

We conducted a retrospective study in 12 hospitals in 5
countries (United States, n = 3; France, n = 2; Germany,
n = 2; Italy, n = 2; and Spain, n = 3). Eligible patients
were aged ≥18 years consecutively admitted for their
index hospitalization within 36 months prior to study
initiation in 2013. All eligible patients met a clinical
diagnosis of NP defined as new or progressive infiltrates
consistent with pneumonia on chest radiograph or computed tomography and either a temperature >38.3°C or
leukocytosis >10,000 cells/mm3 or both. To be eligible,
patients had to have P. aeruginosa cultured from at least
one of the following respiratory specimens, including
sputum, pleural fluid, flexible bronchoscopy with protected specimen brush, bronchoalveolar (BAL), transbronchial biopsy, nonbronchoscopic BAL, or tracheobronchial
aspirate in intubated patients. Microbiologic cultures
(qualitative or quantitative) had to be obtained within the
12-hour window before or the 12-hour window after the
initiation of antibiotic(s) targeting P. aeruginosa. Each
investigator obtained approval and a waiver of patient
consent from an Independent Ethics Committee or Institutional Review Board at their institution before commencing the study. The list of all ethical bodies that approved
the study can be found in the Acknowledgements section.
Endpoints and covariates

The primary endpoints examined were multidrug-resistance
and hospital mortality. We collected important covariates
including demographics, comorbidities (heart failure, diabetes mellitus, chronic obstructive pulmonary disease,
chronic kidney disease, chronic liver disease, hematologic
malignancy, solid tumor, HIV/AIDS, and dementia). In
addition, important process-of-care variables, including
ICU admission, mechanical ventilation, vasopressor administration, and the appropriateness of initial antibiotic
therapy, were collected.
Definitions

To be classified as MDR, the P. aeruginosa isolate had
to be non-susceptible to one or more agents in three or
more of the following antimicrobial categories, as determined by the European Center for Disease Prevention
and Control (ECDC) and the Centers for Disease Control
and Prevention (CDC): aminoglycosides, antipseudomonal
carbapenems, antipseudomonal cephalosporins, antipseudomonal fluoroquinolones, antipseudomonal penicillins
plus β-lactamase inhibitors, monobactams, phosphonic
acids, and polymixins. To be classified as extensively
drug-resistant (XDR), the P. aeruginosa isolate had to be
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non-susceptible to one or more agents in all but two or
more of the aforementioned antimicrobial categories [14].
Antimicrobial treatment was deemed to be appropriate
(AIAT) if at least one of the initially prescribed antibiotics
was active against the identified P. aeruginosa isolate
based on in vitro susceptibility testing and this antibiotic
was administered within 24 hours after collection of the
respiratory specimen [15].
Antimicrobial susceptibility testing

Microbiology laboratories performed antimicrobial susceptibility testing of isolates using disk diffusion or automated
testing methods according to guidelines and breakpoints
established by the Clinical Laboratory and Standards Institute (CLSI) [16] and the European Committee on Antimicrobial Susceptibility Testing (EUCAST) [17].
Statistical analyses

Continuous variables were reported as means with
standard deviation or the median and interquartile range
from non-normally distributed data. Differences between
continuous variables were tested using Student’s t-test or
the nonparametric Mann-Whitney U-test. Categorical
data were summarized as proportions, and the Chisquare test or Fisher’s exact test for small samples was
used to examine differences between groups. Univariate
and multivariate logistic regression models were constructed to identify clinical risk factors associated with
multidrug-resistance. All variables that showed a significant result in the univariate analysis (≤0.10) were included
in the corresponding multivariate logistic regression analysis. All variables entered into the models were examined
to assess for co-linearity, and interaction terms were
tested. The model’s calibration was assessed with the
Hosmer-Lemeshow goodness-of-fit test. A Cox proportional hazards model was constructed to determine variables independently associated with hospital mortality.
This test was selected to exclude the influence of timedependent covariates on hospital mortality and to adequately control for imbalances in baseline and clinical
characteristics when constructing a survival curve. All
tests were two-tailed, and a P-value <0.05 was deemed a
priori to represent statistical significance. All analyses
were performed with SPSS software, version 19.0 (IBM
SPSS, Chicago, IL, USA).

Results
Seven hundred and forty patients with Pa-NP met the inclusion criteria and were enroled in the study: 258 (34.9%)
from the United States, 141 (19.1%) from France, 120
(16.2%) from Germany, 113 (15.3%) from Spain and 108
(14.6%) from Italy. The prevalence of multidrug resistance
was 30.5%. The patients’ baseline and clinical characteristics are shown in Table 1. Patients with pneumonia caused
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Table 1 Clinical and epidemiological characteristics of multidrug (MDR) and non-multidrug resistant patients with
Pseudomonas aeruginosa pneumonia
Characteristic

Percent missing
(of total 740)

MDR
N = 226

Non-MDR
N = 514

P-value

Age, years, mean ± SD

0.5%a

53.5 ± 17.5

62.1 ± 15.5

<0.001

Male

0%

142 (62.8%)

361 (70.2%)

0.047

Location prior to admission

1.1%

Community

101 (44.7%)

286 (55.6%)

0.006

Skilled nursing facility

17 (7.5%)

37 (7.2%)

0.876

Long-term care facility

7 (3.1%)

20 (3.9%)

0.596

Assisted living

4 (1.8%)

3 (0.6%)

0.125

Inpatient rehabilitation

27 (11.9%)

20 (3.9%)

<0.001

Other

66 (29.2%)

144 (28.0%)

0.741

245 (56.3%)

0.307

Past medical history
Hospitalized in the previous 6 months

13.1%

126 (60.6%)

Antibiotics in the previous 30 days

27.6%

100 (57.5%)

163 (45.0%)

0.007

Heart failure

9.6%

49 (23.2%)

131 (28.6%)

0.145

Chronic obstructive pulmonary disease

9.2%

102 (48.8%)

173 (37.4%)

0.005

Diabetes mellitus

8.6%

79 (37.8%)

137 (29.3%)

0.029

Chronic kidney disease

9.3%

55 (26.3%)

118 (25.5%)

0.832

Chronic liver disease

11.9%

38 (18.5%)

70 (15.7%)

0.359

Hematologic malignancy

9.9%

20 (9.4%)

40 (8.8%)

0.807

Solid tumor

10.3%

18 (8.7%)

81 (17.7%)

0.002

HIV/AIDS

10.5%

3 (1.5%)

6 (1.3%)

0.885

Dementia

12.6%

6 (3.0%)

36 (8.1%)

0.015

Charlson score, mean ± SD

2.6%

3.1 ± 2.6

3.0 ± 2.6

0.869

Pneumonia category

0%

Community-onset, healthcare-associated

74 (32.7%)

167 (32.5%)

0.946

Hospital-onset

152 (67.2%)

347 (67.5%)

0.946

Hospital-acquired

50 (22.1%)

112 (21.8%)

0.919

Ventilator-associated

102 (45.1%)

235 (45.7%)

0.883

ICU admission

0%

180 (79.6%)

367 (71.4%)

0.019

Length of ICU stay, days, median (IQR)

0%

18.9 (11.4, 32.5)

16.1 (8.7, 29.1)

0.058

Mechanical ventilation

0%

197 (87.2%)

440 (85.6%)

0.571

Length of mechanical ventilation, days, median (IQR)

0%

17.0 (9.1, 34.1)

13.1 (6.5, 26.0)

0.006

Vasopressor administration

0%

146 (64.6%)

308 (59.9%)

0.229

Bacteremia

0%

53 (23.5%)

128 (24.9%)

0.672

Inappropriate initial antibiotic therapy

1.5%

83 (37.9%)

98 (19.2%)

<0.001

In-hospital mortality

0%

101 (44.7%)

163 (31.7%)

0.001

Length of hospital stay, days, median (IQR)

0%

27.0 (14.0, 56.3)

25.0 (13.0, 46.0)

0.090

a

Four patients aged >90 years (one MDR, three non-MDR) were not included in the calculation.

by MDR strains of P. aeruginosa were significantly younger and were more likely to be admitted to the hospital
from an inpatient rehabilitation facility compared to patients infected with non-MDR strains. Patients with MDR
strains were significantly more likely to have received antibiotics in the 30 days prior to the diagnosis of pneumonia

and were also more likely to have chronic obstructive pulmonary disease and diabetes mellitus. A significantly higher
proportion of patients who were infected with an MDR
strain received IIAT (37.9% versus 19.2%, P <0.001) and
required ICU admission (79.6% versus 71.4%, P = 0.019)
compared to those with a non-MDR strain.
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Susceptibility to all antibiotic classes tested was significantly lower in patients infected with MDR strains
(Table 2). Antibiotic susceptibility by country is found in
Table 3. Germany (44.2%) and Spain (43.4%) were found
to have the highest prevalence of MDR, followed by
France (33.3%), Italy (22.2%) and the United States
(20.5%). Table 4 shows the results of a multivariable logistic regression model that identified the variables associated with pneumonia caused by MDR strains of P.
aeruginosa. Decreasing age in increments of one year,
diabetes mellitus, and ICU admission were independently associated with MDR P. aeruginosa pneumonia.
The overall, hospital mortality was 35.7% (n = 264).
Mortality was significantly different between the United
States and European countries: United States, 22.5%;
France, 37.6%; Germany, 41.7%; Spain, 46.9%; and Italy,
46.3%. Patients with MDR strains had a significantly
higher in-hospital mortality rate compared to non-MDR
infected patients (Table 1). A Cox proportional hazards
model confirmed MDR status as an independent predictor of mortality (hazard ratio (HR) 1.39, 95% CI 1.05
to 1.83, P = 0.021) along with increasing age, heart failure,
concomitant bacteremia, mechanical ventilation, and patients residing in Germany, Italy, and Spain (Table 5). Cox
model-adjusted survival curve analysis controlling baseline
and clinical imbalances confirmed the influence of MDR
on in-hospital mortality (Figure 1).

Discussion
This international investigation representing the largest
cohort study of Pa-NP demonstrated high prevalence of
MDR at 30.5%. Infection caused by MDR P. aeruginosa
was found to be an important determinant of hospital
mortality, thus, it is critical for clinicians to identify patients at risk of MDR from the onset of infection. Our
analysis suggests that the patient’s age, comorbid conditions specifically diabetes, and the severity of infection
as indicated by the need for ICU admission predicts infection with a MDR strain of P. aeruginosa.

The prevalence of MDR Pa-NP is variable depending
on the type of study performed and the participating institutions. A recent large epidemiologic study from the
United States identified 205,526 P. aeruginosa isolates
(187,343 pneumonia; 18,183 bloodstream infection (BSI))
and 95,566 Enterobacteriaceae specimens (58,810 pneumonia; 36,756 BSI) associated with infection [1]. Prevalence of MDR P. aeruginosa (MDR Pa) was approximately
15-fold greater than carbapenem-resistant-Enterobacteriaceae in both infection types. A net rise in MDR Pa as a
proportion of all P. aeruginosa infections occurred from
2000 to 2009. Likewise, data from the National Healthcare
Safety Network (NHSN) in the United States revealed an
increased prevalence of MDR Pa VAP from the period
2007 to 2008 to the period 2009 to 2010, but, it should be
noted the overall prevalence of MDR Pa was 17.7% in the
latter time period, markedly less than our study [3]. The
international composition of the participants is the most
likely explanation for the higher prevalence of MDR
strains in our study.
The literature also varies with respect to the outcomes
of patients with MDR Pa-NP. Peña et al. examined a
Spanish cohort of 91 episodes of ventilator-associated
pneumonia (VAP) in 83 patients, 31 caused by susceptible P. aeruginosa and 60 by MDR Pa strains [18].
These investigators found that susceptible P. aeruginosa
infections were more likely than MDR Pa episodes to receive AIAT and definitive antimicrobial therapy, and in a
logistic regression model IIAT was identified as an independent risk factor for early mortality. A recent metaanalysis supports these findings by demonstrating that
MDR status is an important determinant of mortality due
to nosocomial infections attributed to Gram-negative bacteria, where P. aeruginosa and Acinetobacter species were
the most common isolates [19]. Di Pasquale et al. recently
found MDR status was not associated with a higher rate of
ICU or hospital mortality in patients with ICU-acquired
pneumonia. However, unlike our study, the etiology of infection was a mix of Gram-positive and Gram-negative

Table 2 Antibiotic susceptibility
Antibiotic class

Multidrug-resistant
(n = 226)

Non-multidrug-resistant
(n = 514)

P-value

Aminoglycosides

226 (29.2%)

505 (91.1%)

<0.001

Antipseudomonal carbapenems

226 (15.0%)

508 (84.6%)

<0.001

Antipseudomonal cephalosporins

226 (26.5%)

504 (93.7%)

<0.001

Antipseudomonal fluoroquinolones

222 (21.5%)

502 (88.4%)

<0.001

Antipseudomonal penicillins +

221 (22.2%)

502 (89.0%)

<0.001

Monobactams

158 (13.9%)

208 (81.2%)

<0.001

Phosphonic acids

86 (40.7%)

105 (81.0%)

<0.001

Polymyxins

159 (97.5%)

215 (92.1%)

0.025

β-lactamase inhibitors

Data presented as number of isolates tested (% susceptible). Multidrug-resistant: non-susceptible to one or more agents in three or more antibiotic classes.
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Table 3 Antibiotic susceptibility by country
Antibiotic class

France

Germany

Italy

Spain

United States

Aminoglycosides

141(76.6)

120 (58.3)

101 (75.2)

112 (58.9)

257 (80.2)

Antipseudomonal carbapenems

139 (60.4)

119 (52.1)

107 (57.9)

112 (47.3)

257 (79.0)

Antipseudomonal cephalosporins

140 (77.1)

120 (60.8)

101 (74.3)

111 (59.5)

258 (81.4)

Antipseudomonal fluoroquinolones

138 (66.7)

118 (61.0)

100 (75.0)

111 (52.3)

257 (75.9)

Antipseudomonal penicillins +

141 (64.5)

118 (46.5)

108 (70.3)

110 (63.6)

253 (82.6)

Multidrug-resistant

141 (33.3)

120 (44.2)

108 (22.2)

113 (43.4)

258 (20.5)

Extensively drug-resistant

141 (17.7)

120 (34.2)

108 (2.8)

113 (13.3)

258 (3.5)

β-lactamase inhibitors

Data presented as number of isolates tested (% susceptible). Multidrug-resistant: non-susceptible to one or more agents in three or more antibiotic classes.
Extensively drug-resistant: non-susceptible to one or more agents in all but two or fewer antibiotic classes.

pathogens and there was a small number of MDR Pa
cases (n = 18) [20].
Increasing antimicrobial resistance in P. aeruginosa
infections seems to be the most important predictor of
outcome. In a recent Brazilian study of P. aeruginosa
bacteremia isolates from 120 patients [21], 45.8% were resistant to carbapenems, and 23.3% expressed a metallo-βlactamase gene, blaSPM-1 (57%) or blaVIM-type (43%).
Cefepime-resistance, MDR status and XDR isolates were
independently associated with IIAT, which was an important predictor of mortality. These studies support the importance of appropriate and timely antibiotic therapy as a
potential determinant of outcome for serious infections attributed to P. aeruginosa. Given the association of antibiotic resistance with increasing administration of IIAT
and greater hospital mortality, several strategies have been
developed to improve upon the appropriateness of empiric
therapy in patients at risk of infection with P. aeruginosa
and other antibiotic-resistant pathogens.
A number of investigations have identified risk factors
and scoring systems for infection with MDR pathogens,
including MDR Pa [22-25]. Major limitations of such

approaches are that the potential for IIAT remains, although potentially diminished, and the resultant overuse
of broad-spectrum antibiotics in many patients because of
the non-specificity of the scoring systems. Novel methods
to improve early identification of pathogens and antibiotic
susceptibilities are also entering the diagnostic arena. Such
diagnostic technology advances offer the potential to
maximize administration of appropriate antibiotic therapy
while minimizing unnecessary antibiotic exposure. These
approaches include the use of molecular methods (for example, polymerase chain reaction electrospray ionization
mass spectrometry and matrix-assisted laser desorption/
ionization time-of-flight (MALDI-TOF), as well as advanced automated microscopy techniques that allow the
identification of bacterial species, the presence of antibiotic resistance genes, and bacterial killing by specific
antibiotics within 4 to 6 hours using direct specimen inoculation [26,27].
Our study has a number of limitations. As a retrospective cohort, it is prone to several forms of bias, most notably selection bias. We attempted to mitigate this by
enroling consecutive patients fitting the predetermined

Table 4 Significant univariate and multivariate logistic regression analysis of predictors for multidrug-resistant (MDR)
Pseudomonas aeruginosa pneumonia
Multivariatea

Univariate
Variable

Odds ratio (95% CI)

P-value

Odds ratio (95% CI)

P-value

Age (decreasing increments of 1)

0.97 (0.96, 0.98)

<0.001

0.97 (0.96, 0.98)

<0.001

Male

0.72 (0.52, 0.99)

0.047

1.90 (1.21, 3.00)

0.006

1.73 (1.06, 2.81)

0.028

Residence in a community setting prior to admission

0.64 (0.47, 0.88)

0.006

Residence in an inpatient rehabilitation facility prior to admission

3.35 (1.84, 6.11)

<0.001

Antibiotics in the previous 30 days

1.65 (1.15, 2.38)

0.007

Chronic obstructive pulmonary disease

1.60 (1.15, 2.22)

0.005

Diabetes mellitus

1.46 (1.04, 2.06)

0.030

Solid tumor

0.44 (0.26, 0.76)

0.003

Dementia

0.35 (0.15, 0.85)

0.020

ICU admission

1.57 (1.08, 2.28)

0.019

a

Hosmer-Lemeshow goodness-of-fit test, P = 0.72.
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Table 5 Cox proportional hazards model of significant
predictors for in-hospital mortality
Variable

Hazards ratio
(95% CI)

P-value

Heart failure

1.88 (1.39, 2.52)

<0.001

Age (increasing increments of 1 year)

1.02 (1.01, 1.03)

0.001

Country of origin, Germany

3.05 (1.87, 4.96)

<0.001

Country of origin, Italy

2.38 (1.41, 4.02)

0.001

Country of origin, Spain

1.91 (1.16, 3.14)

0.011

Mechanical ventilation

1.88 (1.02, 3.48)

0.044

Bacteremia

1.67 (1.20, 2.31)

0.002

Multidrug resistance

1.39 (1.05, 1.83)

0.021

No vasopressors

0.61 (0.43, 0.87)

0.006

Healthcare associated pneumonia

0.50 (0.35, 0.73)

<0.001

Variables excluded from the model for co-linearity: aminoglycoside resistance,
carbapenem resistance, fluoroquinolone resistance, penicillin-β-lactamase
inhibitor resistance (co-linear with multidrug resistance); country of origin United States (co-linear with France, Germany, Italy, and Spain). Variables
included but not retained in the model at P <0.05: ICU admission, chronic
kidney disease, chronic liver disease, country of origin - France.

enrolment criteria. Although we adjusted for known confounders, the possibility exists that some residual confounding remains, particularly confounding by indication.
Another important limitation is the potential for patients
to be enroled who did not have true pneumonia. Our use
of clinical criteria along with microbiologic confirmation
was an attempt to maximize the number of patients with
Pa-NP in our cohort. Additionally, antimicrobial susceptibility testing was performed at the local hospital level.
Therefore, the determination of MDR status may have
varied more than if a single reference laboratory was used
to determine the presence or absence of drug resistance. It
is also important to note that although our results strongly
suggest that the association of MDR status with increased risk
of death is mechanistically related to the risk of receiving inappropriate empiric therapy, we cannot rule out that MDR
Pa-NP may exert its lethal effect directly due to higher virulence, as has been suggested with other pathogens exhibiting
higher minimum inhibitory concentration (MIC) to certain
antimicrobials [28,29]. Because we examined hospital mortality rather than the more standard 28-day mortality as the primary outcome for our study, we may have overestimated the
magnitude of this outcome. Last, individual antibiotics
are commonly part of a regimen for the treatment of

Figure 1 Cox proportional hazards model curve comparing patients with multidrug-resistant (MDR)-Pseudomonas aeruginosa and those with
non-MDR P. aeruginosa nosocomial pneumonia.
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nosocomial pneumonia, therefore, independent analysis
of the impact on AIAT may not represent the true prescribing practice at each site.

Conclusions
In summary, our study sheds light on variables associated with to MDR Pa-NP; namely decreasing age, diabetes mellitus and ICU admission. In addition, MDR
status is an independent predictor of hospital mortality
in patients with Pa-NP. Given the high rates of MDR
Pa-NP, advances in rapid diagnosis and susceptibility
analysis are needed to direct antibiotic treatment and
potentially improve outcomes.
Key messages
 Among patients with Pa-NP, presence of infection

with MDR strains is an important independent
predictor for hospital mortality.
 Independent predictors of MDR strains of
P. aeruginosa in this study included decreasing age,
diabetes, and ICU admission.
 Advances in rapid diagnostics and antibiotic
susceptibility analysis are needed to direct antibiotic
treatment and potentially improve outcomes of
patients infected with MDR strains of P. aeruginosa.
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